Theravance Biopharma Inc. (NASDAQ: TBPH) is -7.06% lower on its value in year-to-date trading and has touched a low of $7.53 and a high of $13.17 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The TBPH stock was last observed hovering at around $10.61 in the last trading session, with the day’s loss setting it -0.34% off its average median price target of $10.00 for the next 12 months. It is also 45.95% off the consensus price target high of $19.00 offered by 8 analysts, but current levels are -28.37% lower than the price target low of $8.00 for the same period.
Currently trading at $10.27, the stock is -2.22% and 0.76% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.94 million and changing -3.20% at the moment leaves the stock 7.52% off its SMA200. TBPH registered 21.54% gain for a year compared to 6-month gain of 14.37%.
The stock witnessed a 3.32% loss in the last 1 month and extending the period to 3 months gives it a 10.19%, and is -8.47% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 6.20% over the week and 4.71% over the month.
Theravance Biopharma Inc. (TBPH) has around 158 employees, a market worth around $723.11M and $51.60M in sales. Distance from 52-week low is 36.39% and -22.02% from its 52-week high. The company has generated returns on investments over the last 12 months (-92.80%).
Theravance Biopharma Inc. (TBPH) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Theravance Biopharma Inc. (TBPH) is a “Hold”. 8 analysts offering their recommendations for the stock have an average rating of 2.70, where 3 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Theravance Biopharma Inc. is expected to release its quarterly report on 02/27/2023.The EPS is expected to grow by 35.60% this year
Theravance Biopharma Inc. (TBPH) Top Institutional Holders
The shares outstanding are 75.52M, and float is at 59.84M with Short Float at 12.46%.
Theravance Biopharma Inc. (TBPH) Insider Activity
A total of 8 insider transactions have happened at Theravance Biopharma Inc. (TBPH) in the last six months, with sales accounting for 7 and purchases happening 1 times. The most recent transaction is an insider sale by Hindman Andrew A., the company’s SVP, CHIEF FINANCIAL OFFICER. SEC filings show that Hindman Andrew A. sold 65,000 shares of the company’s common stock on Nov 18 at a price of $11.02 per share for a total of $0.72 million. Following the sale, the insider now owns 0.41 million shares.
Theravance Biopharma Inc. disclosed in a document filed with the SEC on Aug 16 that GRAHAM RICHARD A (SVP, DEVELOPMENT) sold a total of 4,906 shares of the company’s common stock. The trade occurred on Aug 16 and was made at $9.71 per share for $47640.0. Following the transaction, the insider now directly holds 0.36 million shares of the TBPH stock.
Still, SEC filings show that on Aug 09, GRAHAM RICHARD A (SVP, DEVELOPMENT) disposed off 15,086 shares at an average price of $8.79 for $0.13 million. The insider now directly holds 369,651 shares of Theravance Biopharma Inc. (TBPH).
Theravance Biopharma Inc. (TBPH): Who are the competitors?
The company’s main competitors (and peers) include Collegium Pharmaceutical Inc. (COLL) that is trading 15.04% up over the past 12 months and Cumberland Pharmaceuticals Inc. (CPIX) that is -0.86% lower over the same period. Corcept Therapeutics Incorporated (CORT) is 15.56% up on the 1-year trading charts.